by Stacey Hawkins | May 5, 2020 | Oncology
Despite restricted access to parks and beaches due to the COVID-19 pandemic, people everywhere continue to seek solace in outdoor activities, enjoying a walk through the neighborhood or a cold drink on a hot afternoon in a sunny backyard. Fresh air and sunlight are... 
by Stacey Hawkins | Feb 10, 2020 | Immunotherapies
The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—Kymriah (Novartis; Basel, Switzerland) and Yescarta—(Gilead; Foster City, CA) were approved in 2017, and remain one of the hottest immunotherapies on the market today. They work by... 
by Stacey Hawkins | Sep 7, 2017 | Immunotherapies
THE FLASH OF THE FIRST CAR-T Last week’s much anticipated FDA approval of the first chimeric antigen receptor T-cell (CAR-T) therapy for acute lymphocytic leukemia hails as the first gene therapy on the US market. Classified as a “cell-based gene therapy,” Novartis’... 
by Stacey Hawkins | Mar 9, 2017 | Immunotherapies
Basics & Innovations Monoclonal antibody (mAb) therapeutics burst onto the healthcare scene 20 years ago, and today they remain one of the most versatile and effective therapeutics available. The tried and true mAbs are still in high demand, and we suspect this... 
by Stacey Hawkins | Jan 19, 2017 | Immunotherapies
Understanding CAR-T Safety Chimeric antigen receptor therapy (CAR-T) is our top technology pick of 2016, blazing trails in drug development with its innovative approach of using engineered immune cells to fight cancer. Despite its success in clinical trials, safety...
